Advanced Search

O. Reg. 499/05: GENERAL


Published: 2005-09-22

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
 

ontario regulation 499/05

made under the

ontario drug benefit act

Made: September 21, 2005
Filed: September 22, 2005
Printed in The Ontario Gazette: October 8, 2005


Amending O. Reg. 201/96

(General)

1. Section 1 of Ontario Regulation 201/96 is amended by adding the following subsection:

(7) For the purposes of this Regulation, items 392, 393, 394, 395, 396, 398, 1158, 1285, 1286 and 1287 of Part III of the Formulary shall be read as follows:

 


392


2265273


Novo-Warfarin 1mg Tab




393


2265281


Novo-Warfarin 2mg Tab




394


2265303


Novo-Warfarin 2.5mg Tab




395


2265311


Novo-Warfarin 3mg Tab




396


2265338


Novo-Warfarin 4mg Tab




398


2265346


Novo-Warfarin 5mg Tab




1158


2246083


Apo-Ipravent 0.03% Nasal Spray




1285


2245456


Sodium Aurothiomalate 10mg/mL Inj Sol-1mL Pk




1286


2245457


Sodium Aurothiomalate 25mg/mL Inj Sol-1mL Pk




1287


2245458


Sodium Aurothiomalate 50mg/mL Inj Sol-1mL Pk




2. The Regulation is amended by adding the following section:

7.2 A drug product identified by brand name and manufacturer in the following amendments to Part III of the Formulary is designated as a listed drug product unless there is an indication in that Part that the drug product is not a benefit:

1. Amendments dated September 30, 2005.

3. (1) Subject to subsection (2), this Regulation comes into force on September 27, 2005.

(2) Section 2 comes into force on the later of,

(a) September 30, 2005; and

(b) the day that is 10 days after the day of filing, where the following are not included in calculating the 10 days:

(i) the day of filing, and

(ii) Saturdays and Sundays and other holidays within the meaning of the Interpretation Act.

Made by:

George Smitherman

Minister of Health and Long-Term Care

Date made: September 21, 2005.